

# OxySure Systems Inc (OXYS) OTCQB

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

## Key Stock Statistics

Source S &amp; P, company reports, Vickers

Price as of Jan 29, 2014	\$0.74	Trailing 12-Month P/E	NM	Yield (%)	Nil
52-Wk Range	\$1.02–0.35	Tangible Book Val/Share	NM	Total Shares Outstg. (M)	24.2
Trailing 12-Month EPS	\$-0.03	\$10K Invested 5 Yrs Ago	NA	Market Capitalization(B)	\$0.018
Dividend Rate/Share	Nil	Beta	NA	Institutional Ownership (%)	NA

## Corporate Information

**Investor Contact** C. Hansen (972-294-6461)  
**Telephone** 972-294-6450.

**Company Address** 10880 John W. Elliott Drive,  
 Suite 600, Frisco, TX 75033.

**Website** <http://www.oxyure.com>

## Revenue/Earnings Data

Revenue (Million \$)	1Q	2Q	3Q	4Q	Year
2013	0.24	0.48	0.55	--	--
2012	0.03	0.06	0.10	--	0.27
2011	0.05	0.05	0.02	--	0.19
2010	--	--	--	--	0.36
2009	--	--	--	--	0.39
2008	--	--	--	--	--

## Earnings Per Share (\$)


2013	-0.01	-0.01	Nil	--	--
2012	-0.02	-0.01	-0.01	--	-0.04
2011	-0.02	-0.03	-0.02	--	-0.10
2010	--	--	--	--	-0.10
2009	--	--	--	--	-0.15
2008	--	--	--	--	--

Fiscal year ended Dec. 31. Next earnings report expected: NA

## Dividend Data

No Dividend Data Available

## Price Performance



S&P Financial Writer **Rob Conte**

## Operational Review Jan 29, 2014

### Income Statement Analysis & Financial Review

Revenues for the nine months ended September 30, 2013 were \$1.3 million vs. \$0.2 million in the prior year. Gross margin widened 37%, on higher revenues. Research & development expenses were \$0.4 million, as opposed to \$1,814 in 2012. Selling, marketing, general & administrative expenses were \$1 million, as opposed to \$0.7 million in 2012, increasing 30%, and operating loss was \$0.4 million, vs. a loss of \$0.6 million for last year. For the first three quarters of the Fiscal Year, net loss was \$0.4 million (\$0.02 a share), vs. a loss of \$0.7 million (\$0.03 a share) in 2012.

In the third quarter, revenues were \$0.5 million vs. \$0.1 million in the prior year. Gross margin widened 55%, on higher revenues. Research & development expenses were \$0.1 million, as opposed to \$579 for the same period in 2012. Selling, marketing, general & administrative expenses were \$0.3 million, as opposed to \$0.2 million for the same period in 2012, rising 67%, and operating loss for the quarter was \$0 million, vs. a loss of \$0.2 million in the prior-year period. Net loss was \$0.1 million (nil a share), vs. a loss of \$0.1 million (\$0.01 a share) in the third quarter of 2012.

### Key Operating Information

At September 30, 2013, OXYS' cash and cash equivalents were \$4,753, net cash used in operating activities was \$834,526, net cash used in investing activities was \$14,817, and net cash provided by financing activities was \$840,582.

### Recent Developments

In January 2014, OXYS announced that it has closed a \$750,000 private placement with accredited institutional investors. The Company entered into a definitive purchase agreement with the investors pursuant to which the Company has sold 750 units of preferred stock and warrants at a price of \$1,000 per unit. Each unit consists of one share of Series B convertible preferred stock and a warrant to purchase approximately 909 shares of common stock, at an exercise price of \$1.20 per share.

In December 2013, OXYS announced that Pacific Medical Systems, Ltd. has signed an agreement to be the Company's exclusive distributor for OxySure's products in Hong Kong and Macau.

All of the views expressed in this research report accurately reflect our quantitative research models regarding any and all of the subject securities or issuers. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report. This report is for information purposes and should not be considered a solicitation to buy or sell any security. Neither S&P nor any other party guarantees its accuracy or makes warranties regarding results from its usage. Redistribution is prohibited without written permission.

# OxySure Systems Inc (OXYS) OTCQB

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

**Business Summary January 29, 2014**

OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company has developed a safe and easy-to-use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which is designed to make the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems.

OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need. These areas include public and private places and settings where medical emergencies can occur; individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military or other environments deemed to be immediately dangerous to life or health.

The company's technology, process and methodologies involve the creation of USP oxygen from two dry, inert powders. OxySure believes that other available chemical oxygen generating technologies contain hazards that make them commercially unviable for broad-based emergency use by lay rescuers or the general public.

The company's launch product is the OxySure Model 615 portable emergency oxygen system. OxySure believes that the OxySure Model 615 is the only product on the market (as of November 2013) that can be safely pre-positioned in public and private venues for emergency administration of medical oxygen by lay persons, without the need for training.

The OxySure Model 615 emergency oxygen device was cleared by the Food and Drug Administration, or FDA (510k, Class II) for over-the-counter purchase in December 2005. The company believes its product bridges the gap between the onset of a medical emergency and the time first responders arrive on the scene.

OxySure has diversified its product portfolio to include solutions focused on the emergency medical preparedness and respiratory needs of its education, commercial and government customers. The company's solutions include automated external defibrillators (AEDs) and accessories, resuscitation equipment, and respiratory and monitoring equipment and supplies.

OxySure launched the OxySure Model 615 into the K-12 education market in the

United States, and it subsequently diversified into other institutional markets, such as colleges, churches and places of worship, manufacturing facilities and other commercial and municipal buildings. The company plans to continue to pursue institutional customers in these and other vertical markets, both in the United States and internationally.

The company believes that Model 615 is a natural complement and companion product to an AED. OxySure plans to continue to market Model 615 as a companion product to AEDs, and its goal in the foreseeable future is to pursue the placement of the OxySure Model 615 next to as many AEDs as possible, in the United States as well as internationally. However, in the long term, OxySure believes that its Model 615 has the potential to become a standard issue item for public and private settings, just like a fire extinguisher.


The company plans to continue to leverage its core competencies in oxygen, breathing technologies, research and manufacturing to pursue revenue opportunities in new vertical markets, including the military.

On December 18, 2013, OxySure announced that Pacific Medical Systems, Ltd. had signed an agreement to be the company's exclusive distributor for OxySure's products in Hong Kong and Macau. The distribution agreement is for an initial term of three years, renewable thereafter. The minimum sales order commitment required by the agreement comprises a total of 11,800 units of the OxySure Model 615 and OxySure Replacement Cartridges over the initial three-year period.


On January 2, 2014, OxySure announced that it had closed a \$750,000 private placement with accredited institutional investors. Pursuant to a purchase agreement with the investors, OxySure sold units which included shares of Series B convertible preferred stock and warrants to purchase common shares of the company. The net proceeds to the company from the offering, after deducting various expenses, were approximately \$677,000, to be used primarily for general corporate purposes.

OxySure Systems, Inc. was formed in January 2004 and is based in Frisco, Texas.

**Peer Comparison Chart - 1 Year**



**Company vs Market Comparison Chart - 1 Year**



# OxySure Systems Inc (OXYS) OTCQB

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

## Key Growth Rates and Averages

Past Growth Rate (%)	1 Year	3 Years	5 Years	9 Years
Sales	42.11	-15.90	NA	NA
Net Income	NM	NM	NA	NA

## Ratio Analysis (Annual Avg.)

Net Margin (%)	NM	NM	NM	NA
% LT Debt to Capitalization	66.67	272.01	245.63	NA

## Expanded Ratio Analysis

	2012	2011	2010	2009
Price/Sales	78.71	Nil	NA	NA
Price/EBITDA	NM	Nil	NA	NA
Price/Pretax Income	NM	Nil	NA	NA
P/E Ratio	NM	Nil	NA	NA
Avg. Diluted Shares Outstg (M)	19.9	15.9	NA	NA

Figures based on calendar year-end price

## Company Financials Fiscal Year Ended Dec. 31

	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
<b>Per Share Data (\$)</b>										
Tangible Book Value	NM	NM	NM	NM	NA	NA	NA	NA	NA	NA
Cash Flow	-0.03	-0.08	-0.08	-0.12	NA	NA	NA	NA	NA	NA
Earnings	-0.04	-0.10	-0.10	-0.15	NA	NA	NA	NA	NA	NA
Dividends	Nil	Nil	Nil	Nil	NA	NA	NA	NA	NA	NA
Payout Ratio	Nil	Nil	Nil	Nil	NA	NA	NA	NA	NA	NA
Prices:High	2.75	NA	NA	NA	NA	NA	NA	NA	NA	NA
Prices:Low	0.05	NA	NA	NA	NA	NA	NA	NA	NA	NA
P/E Ratio:High	NM	NA	NA	NA	NA	NA	NA	NA	NA	NA
P/E Ratio:Low	NM	NA	NA	NA	NA	NA	NA	NA	NA	NA
<b>Income Statement Analysis (M \$)</b>										
Revenue	0.27	0.19	0.36	0.39	NA	NA	NA	NA	NA	NA
Operating Income	-0.65	-0.87	-0.91	-1.55	NA	NA	NA	NA	NA	NA
Depreciation	0.19	0.20	0.25	0.45	NA	NA	NA	NA	NA	NA
Interest Expense	0.21	0.61	0.42	0.32	NA	NA	NA	NA	NA	NA
Pretax Income	-0.83	-1.53	-1.58	-2.33	NA	NA	NA	NA	NA	NA
Effective Tax Rate	NM	NM	NM	NM	NA	NA	NA	NA	NA	NA
Net Income	-0.83	-1.53	-1.58	-2.33	NA	NA	NA	NA	NA	NA
<b>Bal Sheet &amp; Other Financial Data (M \$)</b>										
Cash	0.01	0.07	0.04	0.07	NA	NA	NA	NA	NA	NA
Current Assets	0.25	0.32	0.31	0.29	NA	NA	NA	NA	NA	NA
Total Assets	1.22	0.95	1.10	1.32	NA	NA	NA	NA	NA	NA
Current Liabilities	1.79	2.56	1.89	0.99	NA	NA	NA	NA	NA	NA
Long Term Debt	0.08	1.17	1.54	1.57	NA	NA	NA	NA	NA	NA
Common Equity	-0.65	-2.78	-2.33	-1.24	NA	NA	NA	NA	NA	NA
Total Capital	0.12	0.28	0.46	0.94	NA	NA	NA	NA	NA	NA
Capital Expenditures	0.03	Nil	Nil	0.02	NA	NA	NA	NA	NA	NA
<b>Cash Flow</b>	<b>-0.63</b>	<b>-1.33</b>	<b>-1.33</b>	<b>-1.88</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>
Current Ratio	0.1	0.1	0.2	0.3	NA	NA	NA	NA	NA	NA
% Long Term Debt of Capitalization	64.8	NM	NM	NM	NA	NA	NA	NA	NA	NA
% Net Income of Revenue	NM	NM	NM	NM	NA	NA	NA	NA	NA	NA
% Return on Assets	NM	NM	NM	NM	NA	NA	NA	NA	NA	NA
% Return on Equity	NM	NM	NM	NM	NA	NA	NA	NA	NA	NA

Data as orig reptd.; bef. results of disc opers/spec. items. Per share data adj. for stk. divs.; EPS diluted. 2010 and 2009 data restated to correct an error. E-Estimated. NA-Not Available. NM-Not Meaningful. NR-Not Ranked. UR-Under Review.

## Quantitative Evaluations

# OxySure Systems Inc (OXYS) OTCQB

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

## Corporate Information

### List of Officers

C. Hansen Investor Contact  
 J.T. Ross Chrmn, Pres, Secy, CFO

### List of Board Members

J.T. Ross  
 J.M. Jones  
 V. Jones  
 D.T. Reed

**Founded** 2004

**Employees (#)** 25

**Stockholders** 349

**Transfer Agents** Action Stock Transfer

**Auditor** Sam Kan & Company

**Subsidiaries**

## Corporate History

INCORPORATED in Delaware Jan. 15, 2004.

## Company Management Bios

### J.T. Ross Chrmn, Pres, Secy, CFO

Mr. Julian T. Ross, M.B.A. is the developer of the OxySure technology and founded OxySure Systems, Inc. in January, 2004. Mr. Ross has been the Chief Executive Officer, President, Chief Financial Officer and Secretary of OxySure Systems, Inc. since its inception in January 2004 and also serves as its Chairman and Principal Accounting Officer. He has raised over \$14 million for OxySure Systems to date. He also built OxySure Systems and all its operations and processes, including the manufacturing operations, spearheaded all regulatory approvals (including FDA approval, ANVISA approval, GSA approval and DOT approval), set up the distribution channels, and took OxySure Systems public in late 2011. He is a high energy, results-oriented individual, and he has over 25 years experience in technology, medical devices and manufacturing, having functioned both in consulting and operational capacities at senior management level. His experience includes at least a decade in corporate finance, including public and private financings, and mergers & acquisitions. He has worked for and with start-ups and established organizations, including Anglo American Corporation, Volt Information Sciences, Tandy Corporation, Merrill Lynch, Ernst & Young, Sun International and Isle of Capri, Inc. Mr. Ross has enjoyed an Academic Scholarship from Shell Petroleum and an Academic Scholarship from the Edwin L. Cox School of Business at Southern Methodist University, where he received an MBA in Finance.


# OxySure Systems Inc (OXYS) otcqb

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

## Stock Performance

Based on S&P 1500 Indexes  
 Month-End Price Performance as of 1/31/14



Note: All Sectors & Sub-Industry information is based on the Global Industry Classification Standard (GICS)

## Sub-Industry Outlook

Our fundamental outlook for the health care equipment sub-industry for the next 12 months is neutral. We continue to view many product categories as historically recession-resistant, and we expect they will continue to grow, albeit more slowly and more irregularly than they did prior to the recent recession. We remain concerned about continued weak demand for elective medical procedures. In addition, growth in procedure rates has slowed in areas we normally view as non-elective, such as cardiac rhythm management, interventional cardiology and orthopedics. However, some equipment makers believe procedure rates for their products may be stabilizing in these categories.

We believe the new medical device tax required by the health care reform law and that took effect this year has prompted the sub-industry to align its cost structure to partially offset the impact of the tax. However, since the levy is income tax deductible, its after-tax effect will be lower, and we therefore view its impact as manageable. Many equipment makers have implemented cost reduction initiatives to help offset the levy.

We expect 2014 revenues to rise in constant currency at a mid- to upper single digit pace, aided by new products, expansion into emerging markets, and, in some cases, acquisitions. Still, we expect extended replacement cycles at U.S. hospitals in some areas, pricing pressures, European austerity measures, lower demand in certain product categories and unfavorable foreign exchange to continue to affect reported growth. In addition, until recently, we had seen sales gains in equipment that hospitals believe can differentiate them from one another and/or offer a possible high return on investment. We now think U.S. hospitals have become more cautious regarding their capital budgets amid the shift in some procedures from inpatient to outpatient settings and pending 2014 health care reform rules.

We see positive longer-term fundamentals, including increasing global demand for quality health care, aging populations and rising R&D outlays, leading to a steady flow of new diagnostic and therapeutic products.

In 2013, the S&P Health Care Equipment Index grew 25.8%, versus a 30.1% rise in the S&P 1500 Composite Index. The gains in 2013 suggest to us that while the sub-industry has been benefiting from the market's growth, investors have been less pleased with the health care equipment makers' performance, as a whole. Nor have they been sanguine in their view of the group's prospects. It was the second slowest advancer in the Health Care group of indices in 2013, due, we believe, to the aforementioned headwinds.

--Phillip M. Seligman

## Sub-Industry: Health Care Equipment Peer Group\*: Based on market capitalization within GICS Sub-Industry

	Stock Symbol	Stk Mkt Cap (M)	Recent Stk (\$)	52 Wk H/L (\$)	Beta	Yield (%)	P/E Ratio	Fair Val Calc(\$)	Quality Ranking	S&P IQ %ile	Ret on Rev (%)	LTD to Cap (%)
<b>OxySure Systems</b>	<b>OXYS</b>	<b>18</b>	<b>0.74</b>	<b>1.02/0.35</b>	<b>NA</b>	<b>Nil</b>	<b>NM</b>	<b>NA</b>	<b>NR</b>	<b>NA</b>	<b>NM</b>	<b>64.8</b>
Akers Biosciences	AKER	11	5.09	5.70/4.84	NA	Nil	NM	NA	NR	NA	NM	NA
Corgenix Medical	CONX	10	0.20	0.25/0.01	1.47	Nil	NM	NA	C	8	NM	NA
Dehaier Medical Systems	DHRM	25	5.48	5.70/1.81	2.22	Nil	9	NA	NR	63	15.1	NA
Dynatronics Corp	DYNT	11	4.22	7.94/2.30	1.00	Nil	NM	NA	B-	37	NM	19.3
Echo Therapeutics	ECTE	13	3.29	11.90/1.84	0.35	Nil	NM	NA	C	5	NM	1.2
Electromed Inc	ELMD	13	1.60	3.50/0.90	0.34	Nil	NM	NA	NR	51	NM	8.7
Escalon Medical Corp	ESMC	15	2.01	2.59/0.99	-0.20	Nil	5	NA	C	3	NM	NA
MELA Sciences	MELA	21	0.69	1.75/0.63	0.64	Nil	NM	NA	NR	1	NM	NA
Medifocus Inc	MFS.C	23	0.20	0.26/0.11	NA	Nil	NM	NA	NR	NA	NA	NA
Pro-Dex Inc	PDEX	11	3.15	3.80/1.80	0.76	Nil	NM	NA	C	2	NM	NA
SANUWAVE Health	SNWV	22	0.59	1.59/0.25	0.54	Nil	NM	NA	NR	NA	NM	NA
Tiger X Medical	CDOM	21	0.09	0.20/0.07	-1.02	Nil	NM	NA	C	40	NM	NA
Verisante Technology	VRS.C	16	0.21	0.65/0.15	NA	Nil	NM	NA	NR	NA	NM	NA
Zynex Inc	ZYXI	11	0.37	0.60/0.20	1.01	Nil	NM	NA	NR	27	3.9	NA

NA-Not Available NM-Not Meaningful NR-Not Rated. \*For Peer Groups with more than 15 companies or stocks, selection of issues is based on market capitalization.

# OxySure Systems Inc (OXYS) OTCQB

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

## Consensus Analyst Opinion

<b>BUY</b>	<b>BUY/HOLD</b>	<b>HOLD</b>	<b>WEAK HOLD</b>	<b>SELL</b>
------------	-----------------	-------------	------------------	-------------


## Companies Offering Coverage

Taglich Brothers, Inc.  
 Zacks Investment Research Inc.

## Consensus vs. Performance


For fiscal year 2013, analysts estimate that OXYS will earn \$-0.02. For the 3rd quarter of fiscal year 2013, OXYS announced earnings per share of \$0.00, representing -0% of the total annual estimate. For fiscal year 2014, analysts estimate that OXYS's earnings per share will remain unchanged with this year's estimate at \$-0.02

## Analyst Recommendations



	No. of Rankings	% of Total	1 Mo. Prior	3 Mos. Prior
Buy	1	50	0	0
Buy/Hold	1	50	0	0
Hold	0	0	0	0
Weak Hold	0	0	0	0
Sell	0	0	0	0
No Opinion	0	0	0	0
<b>Total</b>	<b>2</b>	<b>100</b>	<b>0</b>	<b>0</b>

## Consensus Earnings Estimates



Fiscal Years	Avg Est.	High Est.	Low Est.	# of Est.	Est. P/E
2014	-0.02	NA	-0.04	2	NM
2013	-0.02	-0.02	-0.03	2	NM
2014 vs. 2013	0%	NA	-33%	0%	NA
Q4'14	-0.01	-0.01	-0.01	1	NM
Q4'13	NA	NA	-0.01	2	NM
Q4'14 vs. Q4'13	NA	NA	0%	-50%	NA

# OxySure Systems Inc (OXYS) OTCQB

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

## Glossary

### Quantitative Evaluations

In contrast to our qualitative STARS recommendations, which are assigned by S&P analysts, the quantitative evaluations described below are derived from proprietary arithmetic models. These computer-driven evaluations may at times contradict an analyst's qualitative assessment of a stock. One primary reason for this is that different measures are used to determine each. For instance, when designating STARS, S&P analysts assess many factors that cannot be reflected in a model, such as risks and opportunities, management changes, recent competitive shifts, patent expiration, litigation risk, etc.

### S&P Quality Ranking

Growth and stability of earnings and dividends are deemed key elements in establishing S&P's Quality Rankings for common stocks, which are designed to encapsulate the nature of this record in a single symbol. It should be noted, however, that the process also takes into consideration certain adjustments and modifications deemed desirable in establishing such rankings. The final score for each stock is measured against a scoring matrix determined by analysis of the scores of a large and representative sample of stocks. The range of scores in the array of this sample has been aligned with the following ladder of rankings:

A+ Highest	B Below Average
A High	B- Lower
A- Above Average	C Lowest
B+ Average	D In Reorganization
NR Not Ranked	

### S&P Fair Value Rank

Using S&P's exclusive proprietary quantitative model, stocks are ranked in one of five groups, ranging from Group 5, listing the most undervalued stocks, to Group 1, the most overvalued issues. Group 5 stocks are expected to generally outperform all others. A positive (+) or negative (-) Timing Index is placed next to the Fair Value ranking to further aid the selection process. A stock with a (+) added to the Fair Value Rank simply means that this stock has a somewhat better chance to outperform other stocks with the same Fair Value Rank. A stock with a (-) has a somewhat lesser chance to outperform other stocks with the same Fair Value Rank. The Fair Value rankings imply the following:

- 5-Stock is significantly undervalued
- 4-Stock is moderately undervalued
- 3-Stock is fairly valued
- 2-Stock is modestly overvalued
- 1-Stock is significantly overvalued

### S&P Fair Value Calculation

The price at which a stock should trade at, according to S&P's proprietary quantitative model that incorporates both actual and estimated variables (as opposed to only actual variables in the case of S&P Quality Ranking). Relying heavily on a company's actual return on equity, the S&P Fair Value model places a value on a security based on placing a formula-derived price-to-book multiple on a company's consensus earnings per share estimate.

### Insider Activity

Gives an insight as to insider sentiment by showing whether directors, officers and key employees who have proprietary information not available to the general public, are buying or selling the company's stock during the most recent six months.

### Funds From Operations (FFO)

A financial measure used by REIT's to reflect their operating performance. As reported by co. based on NAREIT definition.

### Volatility

Rates the volatility of the stock's price over the past year.

### Technical Evaluation

In researching the past market history of prices and trading volume for each company, S&P's computer models apply special technical methods and formulas to identify and project price trends for the stock.

### Relative Strength Rank

Shows, on a scale of 1 to 99, how the stock has performed versus all other companies in S&P's universe on a rolling 13-week basis.

### Global Industry Classification Standard (GICS)

An industry classification standard, developed by Standard & Poor's in collaboration with Morgan Stanley Capital International (MSCI). GICS is currently comprised of 10 Sectors, 24 Industry Groups, 67 Industries, and 147 Sub-Industries.

### Exchange Type

ASE - American Stock Exchange; AU - Australia Stock Exchange; BB - Bulletin Board; NGM - Nasdaq Global Market; NNM - Nasdaq Global Select Market; NSC - Nasdaq Capital Market; NYS - New York Stock Exchange; OTN - Other OTC (Over the Counter); OTC - Over the Counter; QB - OTCQB; QX - OTCQX; TS - Toronto Stock Exchange; TXV - TSX Venture Exchange; NEX - NEX Exchange.

**Dividends on American Depositary Receipts (ADRs) and American Depositary Shares (ADSs) are net of taxes (paid in the country of origin).**



**OxySure Systems Inc (OXYS) OTCQB**

**GICS Sector:** Health Care  
**Sub-Industry:** Health Care Equipment

**Required Disclosures****S&P Global Distribution of Quantitative Recommendations**

**In North America:** As of December 31, 2013, Standard & Poor's Quantitative Services North America recommended 36.4% of issuers under coverage with buy recommendations, 54.1% with hold recommendations and 9.5% with sell recommendations.

**In Europe:** As of December 31, 2013, Standard & Poor's Quantitative Services Europe have recommended 37.1% of issuers under coverage with buy recommendations, 41.3% with hold recommendations and 21.6% with sell recommendations.

**In Asia:** As of December 31, 2013, Standard & Poor's Quantitative Services Asia have recommended 34.4% of issuers under coverage with buy recommendations, 59.2% with hold recommendations and 6.4% with sell recommendations.

**Globally:** As of December 31, 2013, Standard & Poor's Quantitative Services globally have recommended 36.3% of issuers under coverage with buy recommendations, 52.5% with hold recommendations and 11.2% with sell recommendations.

**S&P Global Distribution of its Qualitative Recommendations (STARS coverage):**

**In North America:** As of December 31, 2013, Standard & Poor's Quantitative Services North America recommended 36.4% of issuers under coverage with buy recommendations, 54.1% with hold recommendations and 9.5% with sell recommendations.

**In Europe:** As of December 31, 2013, Standard & Poor's Quantitative Services Europe have recommended 37.1% of issuers under coverage with buy recommendations, 41.3% with hold recommendations and 21.6% with sell recommendations.

**In Asia:** As of December 31, 2013, Standard & Poor's Quantitative Services Asia have recommended 34.4% of issuers under coverage with buy recommendations, 59.2% with hold recommendations and 6.4% with sell recommendations.

**Globally:** As of December 31, 2013, Standard & Poor's Quantitative Services globally have recommended 36.3% of issuers under coverage with buy recommendations, 52.5% with hold recommendations and 11.2% with sell recommendations.

**Relevant benchmarks:** In North America the relevant benchmark is the S&P 500 Index, in Europe and in Asia; the relevant benchmarks are generally the S&P Pan Europe BMI Index and the S&P Pan Asia BMI Index.

**For All Regions:** All of the views expressed in this research report reflect Standard & Poor's research models regarding the issuer and securities mentioned in this report. No part of the compensation received by Standard & Poor's was, is, or will be, directly or indirectly, related to the specific recommendation expressed in this research report.

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

**Additional information is available upon request.**

**Other Disclosures**

This report has been prepared by Standard & Poor's and issued by Standard & Poor's or one of its affiliates. In the United States, this research reports is issued by Standard & Poor's Financial Services LLC ("S&P"); in the United Kingdom by Standard & Poor's LLC ("S&P LLC"), which is authorized and regulated by the Financial Services Authority; in Hong Kong by Standard & Poor's LLC, which is regulated by the Hong Kong Securities Futures Commission; in Singapore by McGraw-Hill Financial Singapore Pte. Limited (MHFSPL), which is regulated by the Monetary Authority of Singapore; in Malaysia by Standard & Poor's Malaysia Sdn Bhd ("S&PM"), which is regulated by the Securities Commission; in Australia by Standard & Poor's Information Services (Australia) Pty Ltd ("SPIS"), which is regulated by the Australian Securities & Investments Commission; and in Korea by Standard & Poor's Investment Advisory Services LLC, which is regulated by the Financial Services Commission as a cross-border investment advisory company.

The research and analytical services performed by SPIAS, McGraw-Hill Financial Research Europe Limited, MHFSPL, S&PM, and SPIS are each conducted separately from any other analytical activity of S&P Capital IQ.

This report may also include research notes that were prepared by the Standard & Poor's equity analyst assigned to the company for STARS coverage. These research updates apply different criteria and standards, which may lead to a different view or recommendation on the company and which may at times, contradict the quantitative assessment of a stock. Standard & Poor's or an affiliate may license certain intellectual property or provide pricing or other services to, or otherwise have a financial interest in, certain issuers of securities. A reference to a particular investment or security by Standard & Poor's and/or one of its affiliates is not a recommendation to buy, sell, or hold such investment or security, nor is it considered to be investment advice.

Standard & Poor's and its affiliates provide a wide range of services to, or relating to, many organizations, including issuers of securities, investment advisers, broker-dealers, investment banks, other financial institutions and financial intermediaries, and accordingly may receive fees or other economic benefits from those organizations, including organizations whose securities or services they may recommend, rate, include in model portfolios, evaluate or otherwise address.

This report is for information purposes and should not be considered a solicitation to buy or sell any security. Neither S&P nor any other party guarantees its accuracy or makes warranties regarding results from its usage. Redistribution is prohibited without written permission.

**Disclaimers**

This report is based upon information that we consider being reliable, but neither S&P nor its affiliates warrant its completeness, accuracy, adequacy and it should not be relied upon as such. Neither S&P nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance is not indicative of future results.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. This material is not intended for any specific investor and does not take into account a particular investor's investment objectives, financial situations or needs and is not intended as a recommendation of particular securities, financial instruments or strategies. Before acting on any recommendation in this material, an investor should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

For residents of Brazil. This report (i) contains information of general nature provided for informational purposes only, (ii) should not be construed in any manner as any solicitation or offer to buy, sell or hold any securities or any related financial instruments or products neither as any investment advice and/or recommendation regarding any securities or any related financial instruments or products, (iii) should not be relied upon in assessing whether or not to invest in the securities or in any related financial instruments or products mentioned herein; and (iv) should not be construed in any manner as an offer of any securities or any related financial instruments or products.

For residents of Chile. This report is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors.



# OxySure Systems Inc (OXYS) OTCQB

**GICS Sector:** Health Care

**Sub-Industry:** Health Care Equipment

For residents of the People's Republic of China. This report or any material or information contained or incorporated by reference herein, has not been and will not be submitted to or approved/verified by or registered with the Chinese Securities Regulatory Commission or other relevant governmental authorities in the People's Republic of China (excluding Hong Kong, Macau and Taiwan, the "PRC"). Therefore this may not be supplied to the public in the PRC or used as investment advisory services for the purpose of investing in the PRC. This report will not be presented or otherwise constitute provision of any consultancy or advisory service of securities investment

This report does not constitute an offer to sell or the solicitation of an offer to buy any securities to any person to whom it is unlawful to make the offer or solicitation in the PRC. S&P and its affiliates does not represent that this report or any material or information contained or incorporated by reference therein may be lawfully distributed, or that any securities may be lawfully offered, in compliance with any application registration or other requirements in the PRC, or pursuant to an exemption available thereunder, or assume any responsibility for facilitating any such distribution or offering. In particular, no action has been taken by Standard & Poor's, which would permit a public offering of any securities or distribution of this document in the PRC. Neither this report nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with any applicable laws and regulations.

For residents of Japan: With respect to reports issued to clients in Japan and in the case of inconsistencies between the English and Japanese version of a report, the English version prevails. Neither S&P nor its affiliates guarantee the accuracy of the translation. Assumptions, opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Neither S&P nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance is not necessarily indicative of future results.

For residents of Australia: Disclaimer: Standard & Poor's Information Services (Australia) Pty Ltd (ABN 17 096 167 556) (Standard & Poor's) rating and other opinions are and must be construed solely as statements of opinion and not statements of fact or recommendations to purchase, sell or hold any financial product(s). Conclusions, ratings and opinions are reasonably held at the time of completion but subject to change without notice. Standard & Poor's assumes no obligation to update any information following publication. No warranty, express or implied, is given or made by Standard & Poor's as to the accuracy, timeliness, completeness, merchantability or fitness for any particular purpose of any Standard & Poor's rating, opinion or other information and Standard & Poor's will not be liable to any party in contract or tort (including for negligence) or otherwise for any loss or damage arising as a result of any party relying on any such rating, opinion or other information (except in so far as statutory liability cannot be excluded). Any statement of fact is based on information provided to Standard & Poor's by our

**Summary:** This medical technology company focuses on the design, manufacture and distribution of specialty respiratory and medical solutions.

clients or obtained from sources, which Standard & Poor's considers reliable. Standard & Poor's does not perform an audit in connection with any rating and may rely on unaudited information. Because of the possibility of human or mechanical error by our sources, Standard & Poor's or others, Standard & Poor's does not guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. Readers should make their own inquiries.

**Warning:** Past performance is not a reliable indicator of future performance. Any express or implied Standard & Poor's rating or advice is limited to "General Advice" and based solely on consideration of the investment merits of the financial product(s) alone. The information has not been prepared for use by retail investors and has been prepared without taking account of any particular person's financial or investment objectives, financial situation or needs. Before acting on any advice, any person using the advice should consider its appropriateness having regard to their own or their clients' objectives, financial situation and needs. You should obtain a Product Disclosure Statement relating to the product and consider the statement before making any decision or recommendation about whether to acquire the product. Each rating or other opinion must be weighed solely as one factor in any investment decision made by or on behalf of any adviser and any such adviser must accordingly make their own assessment taking into account an individual's particular circumstances.

Standard & Poor's from time-to-time provides fund managers and other clients with investment data, research software, and other financial planning services. Standard & Poor's is a wholly owned member of The McGraw-Hill Companies, Inc, a New York Corporation. The analytic services and products provided by Standard & Poor's and its associates are the result of separate activities in order to preserve the independence and objectivity of each analytic process. Each analytic product or service is based on information received by the analytic group responsible for such product or service. Standard & Poor's and its associates have established policies and procedures to maintain the confidentiality of non-public information received during each analytic process. Standard & Poor's holds an Australian Financial Services Licence Number 258896. Please refer to Standard & Poor's Financial Services Guide for more information at [www.assirt.com.au](http://www.assirt.com.au). "Standard & Poor's" and "Standard & Poor's" are trademarks of The McGraw-Hill Companies, Inc. Copyright 2008 Standard & Poor's Information Services (Australia) Pty Limited. Certain funds data contained herein may be proprietary to Morningstar, Inc.

For residents of the U.K. - This report is only directed at and should only be relied on by persons outside of the United Kingdom or persons who are inside the United Kingdom and who have professional experience in matters relating to investments or who are high net worth persons, as defined in Article 19(5) or Article 49(2) (a) to (d) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, respectively.

For residents of Singapore - Anything herein that may

be construed as a recommendation is intended for general circulation and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. Advice should be sought from a financial adviser regarding the suitability of an investment, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

Third-party data providers - this report was prepared from data provided by Capital IQ, an affiliate of Standard & Poor's. The model used to determine the quantitative output is managed by Standard & Poor's Investment Advisory Services LLC (SPIAS); an affiliate of Standard & Poor's is used on a non-exclusive basis by SPIAS for its advisory clients. Neither Standard & Poor's nor any of the data providers guarantee the accuracy, timeliness, and completeness or correct sequencing of information or warrant any results from use of the information contained in this report. The information included in this report is subject to change without notice.